# The role of immunoproteasome in diabetes and diabetes-related complications

## TL;DR

This review explores how the immunoproteasome contributes to diabetes and its complications, offering potential new treatment strategies.

## Contribution

The paper provides a comprehensive review of the immunoproteasome's role in diabetes and identifies novel therapeutic strategies.

## Key findings

- The immunoproteasome modulates islet β-cell apoptosis and glycolipid metabolism in diabetes.
- It contributes to diabetic complications through activation of downstream cytokines.
- Understanding its activation could lead to innovative diabetes treatments.

## Abstract

The immunoproteasome represents a specialized isoform of the proteasome that is integral to the processes of antigen presentation and protein degradation. While it is primarily expressed in hematopoietic cells, its expression can also be induced in non-hematopoietic cells in response to various inflammatory stimuli. Recent research has highlighted the role of the immunoproteasome in modulating islet β-cell apoptosis and glycolipid metabolism, both of which are critical mechanisms in the pathogenesis of diabetes. Furthermore, the immunoproteasome has been demonstrated to play a significant role in the development of diabetic complications through the activation of various downstream cytokines. Investigating how the immunoproteasome is activated and involved in the pathophysiological processes of diabetes and its complications may provide innovative and promising approaches for diabetes treatment. This review aims to present a comprehensive summary of current research on the role of immunoproteasome in diabetes and its associated complications, ultimately identifying novel strategies for diabetes management and therapy.